Drugs /

dovitinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
dovitinib
NCI Definition [1]:
A benzimidazole-quinolinone compound and receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.

Clinical Trials

View Clinical Trials for dovitinib

Dovitinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating dovitinib, 1 is phase 2 (0 open).

HER2 Deficient Expression and HER2 Negative are the most frequent biomarker inclusion criteria for dovitinib clinical trials.

Breast carcinoma is the most common disease being investigated in dovitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Dovitinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dovitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tki258, chir-258, dovitinib
Drug Categories [2]:
FGFR1/2/3 inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
CSF1R, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB
NCIT ID [1]:
C76199

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.